[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585118":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":76,"collaborators":78,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":33,"enrollmentInfo":99,"targetDuration":33,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":59,"whyStopped":33,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Aim 2: Patients","Patients will have three discrete skin lesions measured, with lesion area determined by ACTG criteria utilizing the product of longest perpendicular diameters. Patients will also have five 3D snapshots of each of the three target lesions taken, measuring lesion area automatically using SS3D.",[12],"Device: SkinScan3D",{"label":14,"type":6,"description":15,"interventionNames":16},"Aim 3: Patients","Providers will first measure KS lesions using the manual ruler-based method as per usual standard of care for the first three months. After the first three months, providers will switch to using SkinScan3D for KS skin lesion measurement.",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DEVICE","SkinScan3D","A handheld, simple, low-cost, and user-friendly technology that combines liquid lens technology and artificial intelligence (AI).",[9,14],[24],"SS3D",[26],{"name":27,"affiliation":5,"role":28},"Thomas Odeny, MBChB, MPH, PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","314-273-3022",null,"odeny@wustl.edu",[36,57],{"facility":37,"status":38,"city":39,"state":33,"zip":33,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Kenya Medical Research Institute","NOT_YET_RECRUITING","Kisumu","Kenya","KE",{"type":43,"coordinates":44},"Point",[45,46],34.76171,-0.10221,{"lat":46,"lon":45},[49,53,54],{"name":50,"role":31,"phone":51,"phoneExt":33,"email":52},"Elizabeth Bukusi, MBChB, MMED, MPH, PhD","+254 0722 205 901","ebukusi@kemri.go.ke",{"name":50,"role":28,"phone":33,"phoneExt":33,"email":33},{"name":55,"role":56,"phone":33,"phoneExt":33,"email":33},"Victor Mudhune, Bpharm","SUB_INVESTIGATOR",{"facility":58,"status":59,"city":60,"state":33,"zip":33,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Infectious Diseases Institute, Makerere University","RECRUITING","Kampala","Uganda","UG",{"type":43,"coordinates":64},[65,66],32.58219,0.31628,{"lat":66,"lon":65},[69,73,74],{"name":70,"role":31,"phone":71,"phoneExt":33,"email":72},"Aggrey Semeere, MBChB, MMed, MAS, FCP (ECSA)","+256 772 621181","aseeere@idi.co.ug",{"name":70,"role":28,"phone":33,"phoneExt":33,"email":33},{"name":75,"role":56,"phone":33,"phoneExt":33,"email":33},"Fred Okuku, MBChB, MMed",{"type":77,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR",[79,82,85,86],{"name":80,"class":81},"National Cancer Institute (NCI)","NIH",{"name":83,"class":84},"Pensievision","UNKNOWN",{"name":37,"class":6},{"name":87,"class":6},"Makerere University","100585118","precision-imaging-to-evaluate-kaposi-sarcoma-100585118",false,"NCT06898203","Precision Imaging to Evaluate Kaposi Sarcoma","Precision Imaging to Evaluation Kaposi Sarcoma (PRIME-KS)","PRIME-KS","Inclusion Criteria - Aim 2 (Patients):\n\n* Adults age ≥18 years old\n* Histopathology-confirmed Kaposi Sarcoma\n* At least 3 skin lesions\n* Capable of informed consent\n* On treatment for Kaposi Sarcoma\n\nExclusion Criteria - Aim 2 (Patients):\n\n* Patients not initiating Kaposi Sarcoma treatment\n* Very ill patients requiring hospitalization\n\nInclusion Criteria - Aim 3 (Patients):\n\n* Adults age ≥18 years old\n* Histopathology-confirmed Kaposi Sarcoma\n* Capable of informed consent\n* Initiating treatment for Kaposi Sarcoma\n\nExclusion Criteria - Aim 3 (Patients):\n\n* Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2\n* Prior or ongoing Kaposi Sarcoma treatment",true,"ALL","18 Years",{"count":100,"type":101},300,"ESTIMATED","INTERVENTIONAL",[104],"NA","AIMS 2 \\& 3:\n\nIn this study the investigators seek to formally compare reproducibility and accuracy of KS lesion size measurements between SkinScan3D and the current standard of care manual measurement method. The investigators will then test the SS3D device on 100 patients in a variety of real-world practice locations to determine whether the device will be usable, acceptable, appropriate, and feasible in routine care settings.",[107],"Kaposi Sarcoma",[109,107,110,111,112,113,114,115,116],"Global Oncology","Affordable Cancer Technologies","Cancer in People with HIV","Human Centered Design","Discrete Choice Experiment","Medical devices","Low-cost design","Global health","2026-06-29",{"date":119,"type":120},"2026-07-01","ACTUAL",{"date":122,"type":120},"2026-04-10",{"date":124,"type":101},"2029-11-30",{"name":5,"class":6},2]